<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
